Cargando…

Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review

PURPOSE OF REVIEW: Rosai-Dorfman disease (RDD) is a rare histiocytic disorder typically presenting as painless cervical lymphadenopathy. Extranodal involvement is common and may also affect bones. Here, we present a patient with typical nodal disease and multifocal bone manifestations. Further, a sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosheimer, Birgit A., Oppl, Bastian, Zandieh, Shahin, Fillitz, Michael, Keil, Felix, Klaushofer, Klaus, Weiss, Günter, Zwerina, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388731/
https://www.ncbi.nlm.nih.gov/pubmed/28401384
http://dx.doi.org/10.1007/s11926-017-0656-6
Descripción
Sumario:PURPOSE OF REVIEW: Rosai-Dorfman disease (RDD) is a rare histiocytic disorder typically presenting as painless cervical lymphadenopathy. Extranodal involvement is common and may also affect bones. Here, we present a patient with typical nodal disease and multifocal bone manifestations. Further, a systematic literature review was performed to better understand the phenotype, clinical course and treatment options of such patients. RECENT FINDINGS: RDD is a nonmalignant, classically sporadic histiocytosis. Nevertheless, increasing evidence also suggests familial forms of the disease. According to our literature review, bone involvement is exceedingly rare and heterogeneous. Clinical outcome in terms of mortality seems to be favorable in most cases. Currently, therapy strategies include surgical and immunosuppressive treatments, but the optimal treatment of osseous RDD remains to be defined. SUMMARY: Patients with osseous RDD may present to rheumatologists with arthralgia or arthritis. Due to the rarity of the disease, diagnosis and treatment remain challenging. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11926-017-0656-6) contains supplementary material, which is available to authorized users.